These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30040971)

  • 1. Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five.
    Chagas CM; Moss S; Alisaraie L
    Int J Pharm; 2018 Oct; 549(1-2):133-149. PubMed ID: 30040971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
    Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
    Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid-mediated Lipinski's second rule: application to drug design and targeting in cancer.
    Omran Z; Rauch C
    Eur Biophys J; 2014 May; 43(4-5):199-206. PubMed ID: 24687685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer therapy-induced adverse events: practicing damage control.
    Lacouture ME; Lenihan D; Wu S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S1-3. PubMed ID: 22409299
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents.
    Alam MS; Lee DU
    Arch Pharm Res; 2016 Feb; 39(2):191-201. PubMed ID: 26694484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions in metastatic breast cancer.
    Tyler T
    J Oncol Pharm Pract; 2011 Sep; 17(3):236-45. PubMed ID: 20861179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review.
    Verbrugghe M; Verhaeghe S; Lauwaert K; Beeckman D; Van Hecke A
    Cancer Treat Rev; 2013 Oct; 39(6):610-21. PubMed ID: 23428230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Anticancer Therapy: Management of Drug Interactions.
    Rogala BG; Charpentier MM; Nguyen MK; Landolf KM; Hamad L; Gaertner KM
    J Oncol Pract; 2019 Feb; 15(2):81-90. PubMed ID: 30763198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
    Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
    J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
    Foulon V; Schöffski P; Wolter P
    Acta Clin Belg; 2011; 66(2):85-96. PubMed ID: 21630604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.
    Gebbia V; Bellavia G; Ferraù F; Valerio MR
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S49-59. PubMed ID: 22149481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five.
    Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y
    J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins.
    Speck-Planche A; Cordeiro MNDS
    Mol Divers; 2017 Aug; 21(3):511-523. PubMed ID: 28194627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral delivery of anticancer drugs I: general considerations.
    Mazzaferro S; Bouchemal K; Ponchel G
    Drug Discov Today; 2013 Jan; 18(1-2):25-34. PubMed ID: 22951365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
    Divakaruni A; Saylor E; Duffy AP
    J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug conjugates-an emerging approach to treat breast cancer.
    Hasan M; Leak RK; Stratford RE; Zlotos DP; Witt-Enderby PA
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00417. PubMed ID: 29983986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients' online forums.
    Assi S; Torrington E; Cheema E; Hamid AA
    J Oncol Pharm Pract; 2021 Jan; 27(1):108-118. PubMed ID: 32264745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.